| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $249,997 | 1 | 50 |
Sells | $72,820 | 1 | 50 |
| Craig Adam R | Executive Chairman | 1 | $249,997 | 0 | $0 | $249,997 |
| KIRSKE DAVID | Chief Financial Officer | 0 | $0 | 1 | $72,820 | $-72,820 |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at X4 Pharmaceuticals, Inc. have bought $249,997 and sold $72,820 worth of X4 Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at X4 Pharmaceuticals, Inc. have bought $100,562 and sold $417,328 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Craig Adam R (Executive Chairman) — $249,997.
The last purchase of 86,206 shares for transaction amount of $249,997 was made by Craig Adam R (Executive Chairman) on 2025‑10‑23.
| 2026-05-12 | Sale | KIRSKE DAVID | Chief Financial Officer | 16,961 0.1471% | $4.29 | $72,820 | -7.60% | |
| 2025-10-23 | Craig Adam R | Executive Chairman | 86,206 0.7092% | $2.90 | $249,997 | +25.73% | ||
| 2025-05-16 | Baldry Mark | Chief Commercial Officer | 1,032 0.0152% | $2.48 | $2,561 | +23.97% | ||
| 2025-01-24 | Sale | Ragan Paula | President and CEO | 76,473 0.0441% | $0.45 | $34,719 | -74.46% | |
| 2025-01-24 | Sale | DiBiase Mary | Chief Operating Officer | 22,258 0.0128% | $0.45 | $10,094 | -74.46% | |
| 2025-01-24 | Sale | Baldry Mark | Chief Commercial Officer | 29,159 0.0168% | $0.45 | $13,241 | -74.46% | |
| 2025-01-24 | Sale | Arbet-Engels Christophe | Chief Medical Officer | 11,624 0.0067% | $0.45 | $5,284 | -74.46% | |
| 2025-01-24 | Sale | Mostafa Adam S. | Chief Financial Officer | 74,773 0.0431% | $0.45 | $33,947 | -74.46% | |
| 2024-11-15 | Sale | Ragan Paula | President and CEO | 31,897 0.0186% | $0.39 | $12,583 | -68.04% | |
| 2024-11-15 | Baldry Mark | Chief Commercial Officer | 13,404 0.0068% | $0.34 | $4,598 | -68.04% | ||
| 2024-10-15 | Sale | Ragan Paula | President and CEO | 31,897 0.0161% | $0.56 | $17,926 | -63.68% | |
| 2024-10-07 | Sale | Ragan Paula | President and CEO | 239,436 0.1183% | $0.55 | $131,522 | -59.93% | |
| 2024-10-07 | Sale | DiBiase Mary | Chief Operating Officer | 67,695 0.0345% | $0.57 | $38,329 | -59.93% | |
| 2024-10-07 | Sale | Taveras Arthur | Chief Scientific Officer | 76,920 0.0389% | $0.56 | $43,306 | -59.93% | |
| 2024-10-07 | Sale | Baldry Mark | Chief Commercial Officer | 11,127 0.0059% | $0.58 | $6,506 | -59.93% | |
| 2024-10-07 | Sale | Mostafa Adam S. | Chief Financial Officer | 230,645 0.1141% | $0.55 | $126,901 | -59.93% | |
| 2024-09-09 | Sale | DiBiase Mary | Chief Operating Officer | 2,642 0.0016% | $0.66 | $1,738 | -52.23% | |
| 2024-05-17 | Baldry Mark | Chief Commercial Officer | 21,646 0.009% | $0.68 | $14,654 | -38.60% | ||
| 2024-03-11 | Sale | Ragan Paula | President and CEO | 49,678 0.0287% | $0.88 | $43,856 | -25.86% | |
| 2024-03-11 | Sale | DiBiase Mary | Chief Operating Officer | 15,409 0.0089% | $0.88 | $13,591 | -25.86% |
| Craig Adam R | Executive Chairman | 376087 0.3987% | $1.44M | 1 | 0 | |
| KIRSKE DAVID | Chief Financial Officer | 176293 0.1869% | $675,202.19 | 0 | 1 | |
| Ross Michael Jay | 1868961 1.9815% | $7.16M | 1 | 0 | ||
| GORDON CARL L | 1868966 1.9815% | $7.16M | 1 | 0 | ||
| SVLSF V, LLC | 10 percent owner | 1868961 1.9815% | $7.16M | 1 | 0 | |
| MCGUIRE TERRANCE | 1803429 1.912% | $6.91M | 1 | 0 | ||
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 1803429 1.912% | $6.91M | 1 | 0 | |
| Ragan Paula | President and CEO | 1087386 1.1529% | $4.16M | 0 | 40 | |
| NeoMed Innovation V L.P. | 10 percent owner | 867639 0.9199% | $3.32M | 1 | 0 | |
| Nessi Claudio | director | 867639 0.9199% | $3.32M | 1 | 0 | |
| DiBiase Mary | Chief Operating Officer | 490980 0.5205% | $1.88M | 0 | 17 | |
| Gerngross Tillman U. | director | 392821 0.4165% | $1.5M | 1 | 0 | |
| Taveras Arthur | Chief Scientific Officer | 388026 0.4114% | $1.49M | 0 | 6 | |
| EMBL Technology Fund II GmbH & Co. KG | 10 percent owner | 370454 0.3928% | $1.42M | 1 | 0 | |
| Stewart Murray | Interim Chief Medical Officer | 146504 0.1553% | $561,110.32 | 0 | 1 | |
| Meisner Derek M | Chief Legal Officer | 145155 0.1539% | $555,943.65 | 0 | 8 | |
| WYZGA MICHAEL S | director | 76667 0.0813% | $293,634.61 | 1 | 0 | <0.0001% |
| Skerlj Renato | Chief Scientific Officer | 42076 0.0446% | $161,151.08 | 0 | 1 | |
| Baldry Mark | Chief Commercial Officer | 25337 0.0269% | $97,040.71 | 3 | 3 | <0.0001% |
| Arbet-Engels Christophe | Chief Medical Officer | 14207 0.0151% | $54,412.81 | 0 | 1 | |
| Cadavid Diego | Chief Medical Officer | 7107 0.0075% | $27,219.81 | 0 | 1 | |
| Mostafa Adam S. | Chief Financial Officer | 0 0% | $0 | 0 | 21 |
$27,082,337 | 104 | 6.73% | $409.24M | |
$6,125,624 | 95 | -6.06% | $326.59M | |
$1,323,997 | 34 | 0.21% | $431.48M | |
$22,017,898 | 24 | 39.19% | $363.95M | |
$15,467,825 | 18 | 4.98% | $362.62M | |
$101,822,203 | 13 | 84.03% | $329.58M | |
$65,355,913 | 13 | -3.42% | $425.64M | |
$176,565 | 8 | -2.61% | $368.01M | |
$5,529,561 | 8 | 5.30% | $316.52M | |
$17,675,244 | 7 | 92.20% | $357.82M | |
$12,035,408 | 5 | -37.54% | $398.46M | |
$556,839 | 5 | 13.42% | $318.88M | |
$58,352 | 4 | -43.78% | $396.86M | |
X4 Pharmaceuticals, Inc. (XFOR) | $51,688 | 4 | -26.18% | $361.24M |
$208,592 | 4 | 11.22% | $328.02M | |
$2,720,023 | 3 | -11.76% | $418.59M | |
$10,104,842 | 3 | 5.45% | $343.14M | |
$184,294 | 3 | -10.64% | $340.12M | |
$20,020,000 | 1 | -75.24% | $327.12M |
| Increased Positions | 60 | +166.67% | 75M | +465.54% |
| Decreased Positions | 12 | -33.33% | 2M | -12.02% |
| New Positions | 43 | New | 49M | New |
| Sold Out Positions | 4 | Sold Out | 1M | Sold Out |
| Total Postitions | 84 | +133.33% | 89M | +453.52% |
| Bain Capital Life Sciences Investors, Llc | $9,478.00 | 2.8% | 2.44M | +2M | +332.13% | 2025-09-30 |
| Nea Management Company, Llc | $8,689.00 | 2.57% | 2.23M | +2M | +347.14% | 2025-09-30 |
| Bvf Inc/Il | $8,689.00 | 2.57% | 2.23M | +2M | New | 2025-09-30 |
| Nantahala Capital Management, Llc | $8,668.00 | 2.56% | 2.23M | +2M | New | 2025-09-30 |
| Rosalind Advisors, Inc. | $6,009.00 | 1.78% | 1.54M | +2M | New | 2025-09-30 |
| Deep Track Capital, Lp | $4,366.00 | 1.29% | 1.12M | +1M | New | 2025-09-30 |
| Stonepine Capital Management, Llc | $4,109.00 | 1.21% | 1.06M | +1M | New | 2025-09-30 |
| Kingdon Capital Management, L.L.C. | $3,631.00 | 1.07% | 933,332 | +700,000 | +300% | 2025-09-30 |
| Stempoint Capital Lp | $2,161.00 | 0.64% | 555,411 | +555,411 | New | 2025-09-30 |
| Vanguard Group Inc | $1,597.00 | 0.47% | 410,485 | +178,593 | +77.02% | 2025-09-30 |